Highly Reduced Survival in ET and PV Patients with Vascular Complications during Follow-up - Real World Data from the Swedish MPN Registr

Marie Lindgren(Umeå University), Jan Samuelsson(Karolinska University Hospital), Anna Ravn Landtblom(Karolinska University Hospital), Stefan Scheding, Helna Pettersson(NU Hospital Group), Erik Ahlstrand(Örebro University), Maria Liljeholm(University Hospital of Umeå), Björn Andréasson(NU Hospital Group)

Blood

November 13, 2019

10.1182/blood-2019-124374

Cited by 0

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

|Blood|1998|306

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

|The Lancet|2023|194